Media headlines about Joint (NASDAQ:JYNT) have trended somewhat positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Joint earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 48.7883131436359 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern’s analysis:
- The Joint Corp. (JYNT) CEO Peter Holt on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Joint (JYNT) Announces Quarterly Earnings Results (americanbankingnews.com)
- GHR Awarded Healthcare Staffing Accreditation from The Joint Com – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
- The Joint Corp. Reports Second Quarter 2018 Financial Results (finance.yahoo.com)
- The Joint Chiropractic is the Official Chiropractor of University of Houston Athletics (franchising.com)
Several analysts recently commented on the company. ValuEngine raised Joint from a “buy” rating to a “strong-buy” rating in a report on Friday, June 15th. Maxim Group reaffirmed a “buy” rating and issued a $10.00 price target on shares of Joint in a research note on Friday, May 11th. Zacks Investment Research lowered Joint from a “hold” rating to a “sell” rating in a research note on Tuesday, June 12th. Finally, Roth Capital lifted their price target on Joint from $7.75 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, June 7th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Joint presently has a consensus rating of “Buy” and a consensus target price of $9.92.
Joint (NASDAQ:JYNT) last issued its quarterly earnings results on Thursday, August 9th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.02. Joint had a negative return on equity of 29.55% and a negative net margin of 3.72%. The firm had revenue of $7.56 million for the quarter, compared to analyst estimates of $7.62 million. analysts expect that Joint will post 0.06 earnings per share for the current year.
In other Joint news, CFO John P. Meloun sold 40,539 shares of Joint stock in a transaction on Thursday, June 28th. The stock was sold at an average price of $8.01, for a total value of $324,717.39. Following the sale, the chief financial officer now owns 18,922 shares in the company, valued at $151,565.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Peter D. Holt bought 7,125 shares of Joint stock in a transaction on Tuesday, May 15th. The stock was acquired at an average price of $7.74 per share, for a total transaction of $55,147.50. Following the transaction, the chief executive officer now directly owns 50,945 shares of the company’s stock, valued at $394,314.30. The disclosure for this purchase can be found here. Company insiders own 3.20% of the company’s stock.
Joint Company Profile
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of December 31, 2017, the company operated 352 franchised clinics and 47 company-owned or managed clinics.
See Also: Trading Strategy Examples and Plans
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.